In this free virtual session, Columbia experts will provide updates on new therapies for patients with lung cancer. Over the course of the session, presenters will share best practices from Columbia’s multidisciplinary lung cancers team to maximize treatment outcomes while sparing morbidity, as well as exciting new therapies in lung cancer on the horizon. A particular focus will be placed on the role of neoadjuvant medical therapy in lung cancer, minimally invasive surgery after neoadjuvant therapy, and treatment for oligometastic patients.
Regional and national thoracic medical oncologists, thoracic surgeons and radiation oncologists, residents, fellows, and other oncology providers
Upon conclusion of this activity, participants will be better able to:
• Discuss the role of local control of metastatic sites in improving survival of oligometastatic patients.
• Recognize the growing role of neoadjuvant treatment (chemotherapy, immunotherapy, or combination) in lung cancer.
• Discuss contemporary results and indications for surgery after neoadjuvant treatment for lung cancer, and the feasibility of minimally invasive approaches.
5:00 PM | Welcome
Joshua R. Sonett, MD
5:05 PM | The Role for Neoadjuvant Treatment in Resectable Lung Cancer
Catherine A. Shu, MD
5:25 PM | Surgery for Lung Cancer After Neoadjuvant Treatment
B. Payne Stanifer, MD, MPH
5:45 PM | Local Therapy for The Oligometastatic Lung Cancer Patient
Simon K. Cheng, MD, PhD
6:05 PM Q&A
6:30 PM Adjourn
Simon K. Cheng, MD, PhD, Residency Program Director and Assistant Professor of Radiation Oncology
Catherine A. Shu, MD, Professor of Medicine at CUMC
Joshua R. Sonett, MD, Edward C. and Anne K. Weiskopf Professor of Surgical Oncology (in Surgery) at CUMC
B. Payne Stanifer, MD, MPH, Professor of Surgery at CUMC
This activity has been approved for AMA PRA Category 1 Credit™
Thursday, May 6 at 5:00pm to 6:30pmVirtual Event